Neutrophils accumulate in the circulation of patients with cancer, and the neutrophil-to-lymphocyte ratio is a widely used biomarker. However, the effects of neutrophils on tumour development and progression, and the efficacy of therapies, remain relatively unknown. In this Review, the authors draw on data from animal models and patients with cancer to provide an overview of the effects of…
Nature Reviews Clinical Oncology – The development of clinically relevant artificial intelligence (AI) models has traditionally required access to extensive labelled datasets, which inevitably…
Nature Reviews Clinical Oncology – Although ovarian cancer is considered an immunoreactive disease, moderate to no efficacy has been shown in the trials testing immune-checkpoint…
Nature Reviews Clinical Oncology – Endometrial cancer is the commonest gynaecological cancer in economically developed countries, and both the incidence and mortality continue to increase.…
Nature Reviews Clinical Oncology – Endometrial cancer is the commonest gynaecological cancer in economically developed countries, and both the incidence and mortality continue to increase.…
Nature Reviews Clinical Oncology – Patients with advanced-stage hormone receptor-positive (HR+) breast cancer typically receive first-line treatment with anti-oestrogen-based agents, often combined…
On August 19, 2024, the FDA approved lazertinib (Lazcluze, Janssen Biotech, Inc.) with amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) for NSCLC.
Nature Reviews Clinical Oncology – Several different viruses have a role in cancer pathogenesis, contributing to the development of various haematological malignancies and solid tumours…
On August 15, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for resectable non-small cell lung cancer.
Nature Reviews Clinical Oncology – Blinatumomab improves outcomes in adult MRD-negative BCP-ALL
On August 6, 2024, the Food and Drug Administration approved vorasidenib (Voranigo, Servier Pharmaceuticals LLC). Learn more.
